Products.

Done Right.

Shifamed has a history of entrepreneurial success founding cutting edge medical technology companies and bringing highly-valued products to market, either direct or through an acquisition.

We have the experience, knowledge, and a demonstrated ability to discern new technologies that represent compelling business opportunities and structure deals, which provide a rapid return for our investors.

Currently, Shifamed is busy working on several companies that range in development phase from stealth mode and early stage design to commercial release and next generation work. For more information on our portfolio companies, see below or contact them directly.

Current Portfolio Companies

Atia Vision focuses on the development of an accommodating intraocular lens for the ophthalmology market.

NuVera Medical is focused on developing a novel imaging platform for use in a growing number of complex cardiovascular procedures.

Supira Medical is in stealth mode.

Apama Medical, an atrial fibrillation ablation company, was sold in 2017 to Boston Scientific for $175 million in cash up-front, with up to $125 million in milestone payments.

Kalila Medical, a company that provides catheters to address the myriad of delivery and access challenges seen in complex electrophysiology procedures and vascular interventions, was sold to Abbott in 2016 for an undisclosed amount.

Maya Medical, a renal denervation company, was sold in 2012 to Covidien for $60 million in cash up-front, with up to $170 million in milestone payments.

Sadra Medical, a percutaneous aortic valve replacement company, was sold in 2011 to Boston Scientific for $225 million in cash up-front, with up to $225 million in milestone payments.

Embolic Protection, Inc. (EPI), an intravascular filter company, was sold to Boston Scientific in 2001 for $75 million in cash up-front, with an undisclosed amount in milestone payments.

Products.

Done Right.

Shifamed has a history of entrepreneurial success founding cutting edge medical technology companies and bringing highly-valued products to market, either direct or through an acquisition.

Current Portfolio Companies

Legacy Portfolio Companies